COVID-19 pharma news hub
Our COVID-19 hub collates our thoughts on the key considerations and strategies for pharma companies, highlighting emerging patterns in the pharma industry and crucially how these may shape the market in the future.
Please note: COVID-19’s impact on pharma is continually evolving. All insights expressed here are dated individually and were formulated based on the situation at that time.
COVID-19 related news and thought leadership
The future for telehealth and neuroscience in the US
Catalyzed by Covid-19, the accelerated uptake of virtual services within neuroscience has set in motion a reimagining of future healthcare pathways. The new post-pandemic reality is a hybrid virtual/in-person approach for many neurological and psychiatric conditions - driving rapid regulatory change, reduced delivery costs, and improved patient access.
CARe To Understand What Will Shape CAR T’s Future?
CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.
Episode 2: Leading in a crisis
Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series - Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.
COVID-19 – tracking the fast-moving landscape
As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.
COVID-19, China, and Telemedicine
As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.
Launch and COVID-19: Pharma’s Dilemma
COVID-19 is throwing a wrench in years’ worth of launch planning, introducing complications and delays into the regulatory process and severely constricting promotional and educational opportunities for new products. How is the pharmaceutical industry responding to these changes in well-laid plans? How are regulatory bodies responding? We consider the potential impact of the pandemic on launch timing and strategy here.